AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04606446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07248144
Description: KAT6 Inhibitor
Study NCT04606446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Endocrine Therapy
Study NCT04606446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Endocrine Therapy
Study NCT04606446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK4/6 Inhibitor
Study NCT04606446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor
Study NCT03216824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: A dressing is maintained on the CVAD exit site.
Study NCT03216824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-Dressing
Description: The CVAD exit site is not covered with a dressing.
Study NCT04077788 — intervention group
Intervention type: OTHER
Intervention: muscle energy technique
Description: Muscle energy technique:~1. Application of MET for bone of pelvis:~   I) Pubis:~  1. Cranial Os pubis.~  2. Caudal os pubis.~   II) ileum:~  1. Anterior ileum.~  2. Posterior ileum.~  3. External Rotation (In flare) Lesion.~  4. Internal Rotation (Out flare) Lesion.~   III) sacrum:~  1. Forward torsion of sacrum.~  2. Backward torsion of sacrum.~2. Muscle energy technique for specific muscles of pelvis and spine:~   1. Stretch of the Psoas Major.~  2. Stretch of the paravertebral muscle.~  3. Stretch of the piriforms.
Study NCT00106899 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI scans
Study NCT00106899 — intervention group
Intervention type: PROCEDURE
Intervention: Positron Emission Tomography (PET)
Description: PET scans
Study NCT00106899 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar Puncture (LP)
Description: collection of cerebrospinal fluid
Study NCT03817697 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The socio-demographic characteristics of patients, their current and past drug use as well as their knowledge of hepatitis B and vaccination, will be collected via a questionnaire, conducted by the service's addictologists at the beginning of the consultation.
Study NCT02509026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg subcutaneous, once weekly, 24 weeks
Study NCT02499757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flavor and sweetener
Description: maltol added as sweetener to e-cigarette with flavor
Study NCT02499757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flavor and nicotine
Description: 12 mg of nicotine added to e-cigarette with flavor
Study NCT02499757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flavor, nicotine and sweetener
Description: 12 mg nicotine and maltol (sweetener) added to e-cigarette with flavor
Study NCT02499757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flavor
Description: flavored e-cigarette stand alone without added nicotine and maltol (sweetener)
Study NCT04247867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medium cut-off (MCO) dialysis membrane
Description: Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).
Study NCT04247867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fiber mixture (Plantago Psyllium and Inulin)
Description: Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.
Study NCT04247867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber mixture (Plantago Psyllium and Inulin)
Description: Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.
Study NCT04247867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium propionate
Description: Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
Study NCT04247867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium propionate
Description: Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
Study NCT01379508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbivudine
Description: 600 mg film-coated tablets taken as 600 mg once daily
Study NCT01379508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir disoproxil fumarate
Description: 300 mg tablets taken as 300 mg once daily
Study NCT00892346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single ASCT with Thalidomide maintenance
Description: Single ASCT with Thalidomide maintenance:~1. Single Autologous Stem Cell Transplantation: conditioning with Melphalan 200mg/m2 (iv)~2. Thalidomide maintenance: starting from D60 after transplantation at 100-200mg daily (Oral)
Study NCT00942227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy rehabilitation
Description: Extension oriented exercises. Subjects will be instructed in a progression of extension oriented exercises for the lumbar spine
Study NCT00942227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy rehabilitation
Description: Mechanical lumbar traction will be applied with subjects in prone utilizing 40-60% of subject's body weight to create a distraction force in the lumbar spine. Following traction, subjects will be instructed in a progression of extension oriented exercises and manual therapy to increase extension as described for the comparator group.
Study NCT04556799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer-assisted surgery
Description: derotation osteotomy with the aid of 3D osteotomy template and computer-assisted simulated surgery
Study NCT04556799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional osteotomy
Description: traditional osteotomy without the aid of 3D osteotomy template
Study NCT01512511 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nitrous oxide use for pneumoperitoneum creation
Description: use nitrous oxide for create pneumoperitoneum in laparoscopic cholecystectomy
Study NCT01512511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nitrous oxide use for pneumoperitoneum creation
Description: use nitrous oxide for create pneumoperitoneum in laparoscopic cholecystectomy
Study NCT06464822 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: weight control procedures, including intragastric balloon (IGT) \[5\], laparoscopic adjustable gastric banding (LAGB) \[6\], laparoscopic gastric bypass (LGB) operation and laparoscopic sleeve gastrectomy (LSG)
Study NCT00895206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: individual adapted immunosuppression
Description: individual adapted immunosuppression
Study NCT00895206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: golden standard therapy
Description: golden standard therapy
Study NCT04695717 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IVACFLU-S
Description: The Seasonal Inactivated, Split Virion, Trivalent Influenza Vaccine (TIV) were purified by the method of super centrifugation to create gradient segments in sucrose sugar produced by IVAC, or placebo produced by IVAC. Vaccines are produced on eggs, inactivated with formaldehyde. The dose of the vaccine tested was 15 mcg of HA for each antigen component in 0.5 ml.~The influenza virus strains used to produce the 2020-2021 seasonal vaccine will also be provided by the NIBSC, which will be used according to WHO's recommendation, which is expected to include the following Southern Hemisphere strains:~Influenza A / H1N1 strain: Recombinant strain IVR-190 44250 E12 of the strain (A / Brisbane / 02/2018).~Influenza strain A / H3N2: strain IVR-197 (H3N2) 44850 E14 recombinant strain (A / South Australia / 34/2019).~Flu strain B (B / Washington / February 2019).
Study NCT04695717 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IVACFLU-S
Description: The Seasonal Inactivated, Split Virion, Trivalent Influenza Vaccine (TIV) were purified by the method of super centrifugation to create gradient segments in sucrose sugar produced by IVAC, or placebo produced by IVAC. Vaccines are produced on eggs, inactivated with formaldehyde. The dose of the vaccine tested was 15 mcg of HA for each antigen component in 0.5 ml.~The influenza virus strains used to produce the 2020-2021 seasonal vaccine will also be provided by the NIBSC, which will be used according to WHO's recommendation, which is expected to include the following Southern Hemisphere strains:~Influenza A / H1N1 strain: Recombinant strain IVR-190 44250 E12 of the strain (A / Brisbane / 02/2018).~Influenza strain A / H3N2: strain IVR-197 (H3N2) 44850 E14 recombinant strain (A / South Australia / 34/2019).~Flu strain B (B / Washington / February 2019).
Study NCT02109185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.
Study NCT02109185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasonex® Nasal Spray, 50 μg/actuation
Study NCT02109185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasonex® Nasal Spray Suspnsn, 50 μg/actuation
Study NCT02109185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray, 50 μL/actuation
Study NCT03795246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Consultation
Description: Consultation in oncology: collection of oncological data and ongoing cancer treatments, clinical exam Consultation in gynecology: collection of gynecological data, contraception and reproductive medicine
Study NCT03795246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological Test
Description: Blood test:~* FSH, LH, E2 and AMH~* 4 tubes of 7 mL
Study NCT03795246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic Ultrasound
Description: Antral Follicles Count
Study NCT02130791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep
Study NCT01933568 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: combined CFRT and SABR with concurrent cisplatin
Study NCT01933568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: combined CFRT and SABR with concurrent cisplatin
Study NCT01440192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDA001 (cenplacel-L)
Description: 1 unit PDA001 (approximately 200 x 106 cells) IV on Days 1 \& 8
Study NCT04475887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Carboxymaltose
Description: see above
Study NCT04475887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: see above
Study NCT03055130 — intervention group
Intervention type: OTHER
Intervention: Thinprep Cytology Test (TCT) and HPV infection types were tested by gynecologist
Study NCT04730219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles
Study NCT04730219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel 200mg will be administered on Day 2 every 3 weeks for 3 cycles
Study NCT00990704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: Intravenous administration 3 times a week immediately before completion of dialysis
Study NCT00990704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maxacalcitol
Description: Intravenous administration 3 times a week immediately before completion of dialysis
Study NCT02897440 — intervention group
Intervention type: PROCEDURE
Intervention: Full Repairng of soft tissue surrounding the hip
Description: Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
Study NCT02897440 — intervention group
Intervention type: PROCEDURE
Intervention: Partial Repairng of soft tissue surrounding the hip
Description: Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
Study NCT00714727 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: acupuncture
Description: 8 weeks of acupuncture, starting with twice a week for 4 weeks, followed by once a week for 4 weeks, using 8 standardized, bilateral acupuncture points.
Study NCT03710200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bologna 00+S. cerevisiae yeast
Description: Bologna 00 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL of water
Study NCT03710200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bologna 1+S. cerevisiae yeast
Description: Bologna 1 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
Study NCT03710200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio2+S. cerevisiae yeast
Description: Bio2 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
Study NCT03710200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICARDA+S. cerevisiae yeast
Description: Icarda bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
Study NCT03710200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bologna 1+sourdough
Description: Bologna 1 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
Study NCT03710200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio 2+sourdough
Description: 109g of Bio2 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
Study NCT03710200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICARDA+sourdough
Description: Icarda bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
Study NCT03710200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grossi+sourdough
Description: Grossi bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
Study NCT03894813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics and Metronidazole
Description: Oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (qd, 30 days)+Metronidazole Suppositories (qd, 7 days)
Study NCT03894813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Vaginal
Description: Metronidazole Suppositories,qd, 7 days
Study NCT02476539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay022
Study NCT02941718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Advancement Counseling
Description: Participants will receive cognitive behavioral counseling on achieving adequate sleep duration.
Study NCT02941718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Information
Description: Participants will receive educational information on general health topics including diet, physical activity, skin protection, oral health and cancer screenings.
Study NCT04422678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Adding treatment by imatinib oral tablet into the standard treatment for moderate to severe COVID-19 pneumonia.
Study NCT04422678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care for the Moderate to Severe COVID-19 Pneumonia as per the Egyptian National Protocol by the Ministry of Health.
Study NCT03056508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise plus nutrition
Description: On the same day as the exercise class, participants will also receive nutrition support. Participants will alter their overall diet to be consistent with recommendations outlined in our brain health food guide (BHFG) and receive diet counseling and strategy training to promote retention and enable this dietary change. For the first two months, diet group sessions will be held on a weekly basis. For the remaining four months, sessions will be divided between group sessions and individual meetings with study dietitians, on a predefined schedule. Participants will submit weekly logs outlining diet goals, plans, successes and obstacles to help direct identification of sequential goals.
Study NCT03056508 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise (4 additional aerobic and 2-3 resistance training sessions per week) will be monitored by an exercise diary. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% VO2-peak. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of VO2-peak and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
Study NCT03038828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukocyte Interleukin, Injection
Description: Immunotherapy
Study NCT01677377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Oral risperidone was supplied as 2, 3, or 4 mg tablets in blister packs or bottles and taken daily only during the oral dosing periods of the study, days -14 through -8 (if applicable), days -7 through -1, and days 85 through 87.
Study NCT01677377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: RBP-7000 60 mg, 90 mg, and 120 mg were a mixture of the ATRIGEL® Delivery System and 60 mg, 90 mg, or 120 mg risperidone, respectively. Treatment was delivered as subcutaneous injections on study days 1, 29 and 57.
Study NCT03204734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.
Study NCT03204734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endocrine therapy
Description: endocrine therapy will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or surgery in the inhibition of ovarian function.
Study NCT00660634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Revascularization
Description: Angioplasty/Stenting of femoro-popliteal lesions
Study NCT05252780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Body, My Rhythm, My Voice
Description: My Body was a behavioral intervention informed by the social cognitive and self-determination theories. Based on the discussions and a systematic review of the literature, we designed the 8-week, 3 times/week rumba physical activity intervention. The goal of the intervention was to gradually increase all participants' physical activity levels to achieve significant health benefits. As part of the physical activity intervention, participants were also taught by their instructor during each class how to utilize behavioral and cognitive self-regulatory skills to increase and maintain their physical activity participation. Examples of such skills were action planning, coping planning, counter conditioning, self-evaluation, among others.
Study NCT04082819 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Contec CMS50EW
Description: Participants' blood pressure will be measured 3 times with the wearable finger pulse oximeter at their study visit.
Study NCT04082819 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sphygmomanometer
Description: Participants' blood pressure will be measured 4 times manually with a blood pressure cuff at their study visit.
Study NCT02656693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online weight management program
Description: Patients who are enrolled in one of the two arms using the online weight management program (BMIQ) will complete structured educational sessions, follow specific calorie goals and meal plans, participate in self-monitoring activities (i.e., regular tracking of weight, diet, and physical activity), and interact with other features of the program.
Study NCT02656693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Population health management support
Description: Patients will receive weight-related population health management support from their primary care practice; their online weight management program data will be monitored by the population health manager, who will conduct outreach with patients at designated points according to the protocol.
Study NCT01271296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liquorice
Description: 24 gram liquorice eq. to 150 mg glycyrrhizinic acid, taken orally, for three days.
Study NCT01271296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grapefruit Juice
Description: 200 ml pink grapefruit juice three times a day, taken orally, for three days.
Study NCT02111759 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: knee flexion angle 1
Description: 0 degrees of knee flexion during ACL graft fixation
Study NCT02111759 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: knee flexion angle 2
Description: 30 degrees of knee flexion during ACL graft fixation